Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CAT-II: REGN7508 vs Apixaban for Cancer-Associated Venous Thromboembolism
jRCT2031260404Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of REGN7508 in cancer-associated thrombosis (CAT), venous thromboembolism (VTE), deep vein thrombosis (DVT) and 1 more (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment-Emergent Adverse Events (TEAEs) in Part 1, Severity of TEAEs in Part 1 and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
REGN7508
03
Conditions
cancer-associated thrombosis (CAT)venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on jRCT2031260404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260404.